# An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

> **NCT05649722** · PHASE2,PHASE3 · COMPLETED · sponsor: **Insmed Incorporated** · enrollment: 31 (actual)

## Conditions studied

- Pulmonary Hypertension
- Interstitial Lung Disease

## Interventions

- **DRUG:** Treprostinil Palmitil Inhalation Powder
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05649722
- **Lead sponsor:** Insmed Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-11
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05649722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05649722, "An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05649722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*